While weak D antigen expression associated with hemolytic disease of the fetus and newborn (HDFN) is recognized as a distinct phenotype, much remains a mystery with regards to its underlying mechanisms and how best to treat it, according to a study recently published in the World Journal of Experimental Medicine.
Aside from the binary view of Rhesus-compatibility as being determined by the presence/absence of Rhesus isoimmunization, recent research suggests that five Rhesus antigens are clinically relevant: C, c, D, E, and e.
At its most fundamental level, the weak D phenotype is characterized by changes in amino sequences in the structure, driving a reduced D antigen expression. Scientists have gained a much better understanding of the weak D phenotype; today, they have identified a cohort of more than 50 weak D types.
Weak D diagnosis and treatment
The detection of weak D remains a challenge. The two most important tools in this regard are polymerase chain reaction and DNA sequencing; these have allowed physicians to identify weak D more accurately.
Read more about HDFN testing and diagnosis
There is much more work to be done to improve outcomes among patients who have been found to have the weak D antigen, the authors stated, adding that there is an urgent need for research that assesses how RhD genotyping is best carried out and whether it should include high-throughput genotyping and refined artificial intelligence algorithms. Furthermore, the authors stated public education on weak D phenotypes and their implications in pregnancy should be made increasingly available.
If a mother who has been found to have a weak D phenotype has a Rhesus-positive child, there remains a risk of sensitization. To prevent this, Rho(D) immune globulin is typically administered, but the threshold at which this is necessary remains up to debate. Non-invasive tests to assess fetal Rhesus D status can be performed using cell-free fetal DNA from maternal plasma genotyping, which may be effective in predicting Rhesus incompatibility and reducing the unnecessary need for Rho(D) immune globulin administration.
“Clinicians should integrate molecular testing into routine RhD assessment to minimize alloimmunization risks and ensure precise patient care decisions,” the authors wrote.
Sign up here to get the latest news, perspectives, and information about HDFN sent directly to your inbox. Registration is free and only takes a minute.
